Sign in Subscribe
Pharmaceutical industry

MorphoSys AG and AbD Serotec Secure Exclusive License to Research Antibody from The Institute of Cancer Research

Strategic Insights

— 1 min read

MorphoSys AG, a leading biotechnology company, has announced that its research and diagnostic antibodies unit, AbD Serotec, has signed a license agreement with The Institute of Cancer Research (ICR), London, to commercialize a widely used BrdU antibody clone for research applications. The agreement grants AbD Serotec worldwide exclusive rights to develop and market the antibody, which is a crucial tool for studying cell proliferation and kinetics in living tissues and tissue samples.

Key Takeaways:

  • The license agreement provides AbD Serotec with exclusive worldwide rights to commercialize the BrdU antibody clone BU1/75 (also known as ICR1) for research applications.
  • The antibody is a powerful tool for detecting cell proliferation and kinetics in living tissues and tissue samples, allowing for easy and rapid analysis of tumor cell growth kinetics with high accuracy.
  • The agreement complements AbD Serotec's comprehensive range of high-quality cell biology reagents, covering key research areas such as apoptosis, cancer, cell signaling, and cell morphology.
  • The BrdU antibody will be available in various formats, including ELISA, flow cytometry, and immunohistochemistry.
  • The license agreement strengthens AbD Serotec's position as a source of core reagents for studying cell proliferation and kinetics.

Statistics:

  • The BrdU antibody is widely used in the detection of proliferating cells in living tissues and tissue samples.
  • The antibody is incorporated into DNA during DNA synthesis, allowing for easy detection and analysis of cell proliferation and kinetics.
  • AbD Serotec will be the sole supplier of the BrdU antibody, providing researchers with a reliable and high-quality source of this critical reagent.
  • The agreement covers research applications, with the possibility of future expansion to therapeutic and diagnostic uses.

Sources:

  • MorphoSys AG, AbD Serotec Secures Exclusive Worldwide License to Research Antibody from The Institute of Cancer Research (Nov 04, 2010)
  • The Institute of Cancer Research (ICR), About Us (www.icr.ac.uk)

Read more